KIT and colorectal carcinoma: By analysis of pre- and post-treatment samples, we recently demonstrated that imatinib mitigates the aggressive features of CMS4 CRC in this clinical study (Peters et al., submitted [34]), lending support for the concept of KIT-targeted treatment in the clinical management of CMS4 CRC [35].